Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-08-2010 | Original Paper

The clinical significance of ¹⁸F-FDG-PET/CT in early detection of second primary malignancy in cancer patients

Authors: Haoping Xu, Miao Zhang, Ge Zhai, Biao Li

Published in: Journal of Cancer Research and Clinical Oncology | Issue 8/2010

Abstract

Purpose

This retrospective study evaluated the diagnostic value of integrated whole-body ¹⁸F-fluorodeoxyglucose positron-emission tomography and computed tomography (¹⁸F-FDG-PET/CT) in early detection of second primary malignancies in cancer patients.

Materials and methods

From June 2007 to October 2008, 677 cancer patients who had undergone a whole-body ¹⁸F-FDG-PET/CT imaging for the purpose of initial tumor work-up were included in this study. We retrospectively analyzed the follow-up results of patients with newly detected lesions presented on the ¹⁸F-FDG-PET/CT images, which had not been previously detected by other modalities. We diagnosed suspected second primary malignancies by considering PET/CT images and clinical information as well. With the pathological results as the golden standard and complementary clinical follow-up investigations, the sensitivity and the positive-predictive value (PPV) of diagnosis of a second primary malignancy were calculated.

Results

We retrospectively analyzed the follow-up results of 338 patients with newly detected lesions. Twenty-one patients were finally diagnosed with second primary malignancies. In addition, the second primary malignancies of 17 patients were diagnosed at an early stage (P = 0.007). Thirteen patients were without any related symptoms which are indicative of second primary malignancies (P = 0.38). The median Karnofsky performance status scale of these patients in the last follow-up study was 80 points. The sensitivity of ¹⁸F-FDG-PET/CT in detecting a second primary malignancy was 95.24%, the PPV was 74.07%, which was much higher than the PPV of diagnosing with no clinical information.

Conclusion

¹⁸F-FDG-PET/CT is a useful tool in detecting second primary malignancies in an early stage and can improve the therapeutic effects experienced by the patients.

Agress H, Cooper BZ (2004) Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathological comparison. Radiology 230:417–422CrossRefPubMed

Balink H, Krabbe CA, de Visscher JG (2007) The value of PET-CT imaging in malignant tumours of the head and neck. Ned Tijdschr Geneeskd 151(21):1167–1172PubMed

Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, Altman H, Keidar Z, Israel O (2003) The clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 44:1200–1209PubMed

Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L, Nutt R (2000) A combined PET/CT scanner for clinical oncology. J Nucl Med 41:1369–1379PubMed

Braakhuis BJ, Tabor MP, Leemans CR, van der Waal I, Snow GB, Brakenhoff RH (2002) Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck 24:198–206CrossRefPubMed

Choi JY, Lee KS, Kwon OJ, Shim YM, Baek CH, Park K, Lee KH, Kim BT (2005) Improved detection of second primary cancer using integrated [¹⁸F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging. J Clin Oncol 23(30):7654–7659CrossRefPubMed

Cook GJR, Wegener EA, Fogelman I (2004) Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. Semin Nucl Med 34:122–133CrossRefPubMed

Dong C, Hemminki K (2001) Second primary neoplasms in 633, 964 cancer patients in Sweden, 1958–1996. Int J Cancer 93(2):155–161CrossRefPubMed

Ishimori T, Patel PV, Wahl RL (2005) Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med 46(5):752–757PubMed

Israel O, Yefremov N, Bar-Shalom R, Kagana O, Frenkel A, Keidar Z, Fischer D (2005) PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance. J Nucl Med 46(5):758–762PubMed

Kim SY, Roh JL, Yeo NK, Kim JS, Lee JH, Choi SH, Nam SY (2007) Combined ¹⁸F-fluorodeoxyglucose-positron emission tomography and computed tomography as a primary screening method for detecting second primary cancers and distant metastases in patients with head and neck cancer. Ann Oncol 18:1698–1703CrossRefPubMed

Shen YY, Su CT, Chen GJ, Chen YK, Liao AC, Tsai FS (2003) The value of ¹⁸F-fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening. Neoplasma 50:217–221PubMed

Stokkel MP, Moons KG, ten Broek FW, van Rijk PP, Hordijk GJ (1999) ¹⁸F-Fluorodeoxyglucose dual-head positron emission tomography as a procedure for detecting simultaneous primary tumors in cases of head and neck cancer. Cancer 86:2370–2377CrossRefPubMed

Travis LB (2006) The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev 15(11):2020–2026CrossRefPubMed

Warren S, Gates O (1932) Multiple malignant tumors: a survey of literature and statistical study. Am J Cancer 16:1358–1414

Yasuda S, Ide M, Fujii H, Nakahara T, Mochizuki Y, Takahashi W, Shohtsu A (2000) Application of positron emission tomography imaging to cancer screening. Br J Cancer 83:1607–1611CrossRefPubMed

Title: The clinical significance of 18F-FDG-PET/CT in early detection of second primary malignancy in cancer patients
Authors: Haoping Xu
Miao Zhang
Ge Zhai
Biao Li
Publication date: 01-08-2010
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 8/2010
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-010-0759-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2010

Potential roles for PA28β in gastric adenocarcinoma development and diagnosis

Epigenetic silencing of WIF-1 in hepatocellular carcinomas

Analysis of related factors associated with radiation pneumonitis in patients with locally advanced non-small-cell lung cancer treated with three-dimensional conformal radiotherapy

Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases

Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients

Semi-quantitative detection of GADD45-gamma methylation levels in gastric, colorectal and pancreatic cancers using methylation-sensitive high-resolution melting analysis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials